Zhou X D, Tang Z Y
Liver Cancer Institute, Zhong Shan Hospital, Shanghai, China.
Gan To Kagaku Ryoho. 1997 May;24 Suppl 1:9-16.
This paper reports the progress of management in 2639 patients with pathologically proven primary liver cancer (PLC) over the past three decades, and the factors improving long-term outcome. The 5-, and 10-year survival after resection of PLC was 45.9% and 34.8%, respectively, for the whole series (n = 1826), and 61.3% and 45.7%, respectively, for patients with small PLC (< = 5 cm, n = 645). The 5-year survival after cryosurgery was 37.9% for the whole series (n = 191), and 53.1% for patients with small PLC (n = 56). The 5-year survival of 73 patients receiving sequential resection after cytoreduction therapy was 67.8%. The 5-year survival after re-resection for recurrence tumor (n = 148) was 34.5%; 239 patients survived more than 5 years; 124 of these patients (51.9%) were small PLC, and 63 patients survived more than 10 years. Encouraging changes in the prognostic pattern were observed when the PLC data of 1958-1970 (n = 178), 1971-1982 (n = 582) and 1983-1994 (n = 1879) were compared; the 5-year survival being 4.8%, 11.2% and 45.4%, respectively, and the 10-year survival being 4.2%, 7.5% and 34.6%, respectively. Some aspects to prolong survival further were discussed.
本文报告了过去三十年中2639例经病理证实的原发性肝癌(PLC)患者的治疗进展以及改善长期预后的因素。整个系列(n = 1826)PLC切除术后的5年和10年生存率分别为45.9%和34.8%,小PLC(≤5 cm,n = 645)患者的5年和10年生存率分别为61.3%和45.7%。整个系列(n = 191)冷冻治疗后的5年生存率为37.9%,小PLC(n = 56)患者的5年生存率为53.1%。73例接受细胞减灭治疗后序贯切除的患者5年生存率为67.8%。复发性肿瘤再次切除术后(n = 148)的5年生存率为34.5%;239例患者存活超过5年;其中124例(51.9%)为小PLC,63例患者存活超过10年。比较1958 - 1970年(n = 178)、1971 - 1982年(n = 582)和1983 - 1994年(n = 1879)的PLC数据时,观察到预后模式有令人鼓舞的变化;5年生存率分别为4.8%、11.2%和45.4%,10年生存率分别为4.2%、7.5%和34.6%。还讨论了进一步延长生存期的一些方面。